Highlights

  • COO Karen Massey to transition into CEO and Executive Director role
  • Current CEO Tim Van Hauwermeiren to become non-Executive Director and Chairman
  • Board changes subject to shareholder approval at May 2026 AGM

argenx SE (NASDAQ:ARGX) has announced a series of planned leadership transitions involving its executive team and Board of Directors. The company said current Chief Operating Officer Karen Massey will move into the role of Chief Executive Officer and Executive Director, while current Chief Executive Officer Tim Van Hauwermeiren will transition to the role of non-Executive Director and Chairman of the Board.

The changes are subject to shareholder approval at the company’s Annual General Meeting scheduled for May 6, 2026. According to argenx, the timeline allows for a structured and comprehensive transition period. As part of the update, Tim Van Hauwermeiren is expected to succeed Peter Verhaeghe, who will retire from the Board after serving since 2008.

Board and Executive Transition

Peter Verhaeghe, current Chairman of the Board of Directors, commented on the leadership evolution and his upcoming retirement.
“This leadership evolution comes at the right time and represents a natural step as we prepare for the next phase of growth at argenx - a long-term future that remains bold, patient-focused, and built to last,” said Peter Verhaeghe, Chairman of the Board of Directors. “I am proud to have been part of this journey in building a leading biotech company from the start. The Board and I move forward with strong confidence in Tim as our incoming Chairman, Karen as our trusted COO and incoming CEO, and the entire leadership team, to guide the organization towards Vision 2030 and beyond.”

Leadership Continuity and Roles

Tim Van Hauwermeiren, co-founder and current Chief Executive Officer, outlined his perspective on the transition and his future responsibilities as Chairman.
“My ambition has always been to build a strong, independent biotech company for the long-term. This transition is the next step in that evolution and Karen is the right person to lead our company forward,” said Tim Van Hauwermeiren. “As Chairman, I will be a sounding board to Karen and the team on long-term strategy, stay close to the innovation mission by engaging with the external ecosystem and lead the Board’s evolution to facilitate our next phase of growth.”

Incoming CEO Outlook

Karen Massey, who joined argenx three years ago and currently serves as Chief Operating Officer, also shared remarks on her upcoming role.
“This is a special company with a bright future that is founded on the strength of our science, our entrepreneurial culture, and the deep accountability of our talented teams to transform the lives of our patients,” said Karen Massey. “My commitment is to elevate the unique argenx DNA as we execute on Vision 2030 and beyond.”

About argenx

argenx is a global immunology company focused on developing antibody-based medicines for severe autoimmune diseases. Through its Immunology Innovation Program, the company collaborates with academic researchers to translate immunology research into therapeutic candidates. argenx has developed and commercialized an approved neonatal Fc receptor blocker and continues to evaluate its potential across multiple autoimmune indications while advancing earlier-stage programs.

LAES closed at USD 839.99 on January 02, 2026.